Kymera Therapeutics Inc (KYMR)

07:35 AM

Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus

07:35 AM

07:26 AM

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times

07:26 AM

07:00 AM

Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan

07:00 AM

Apr 17, 2025

Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com

Apr 17, 2025

Apr 11, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World

Apr 11, 2025

Apr 10, 2025

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN

Apr 10, 2025

Apr 10, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus

Apr 10, 2025

Apr 10, 2025

Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz

Apr 09, 2025

Apr 09, 2025

Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan

Apr 09, 2025

Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 07, 2025

Apr 06, 2025

KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 06, 2025

Apr 01, 2025

(KYMR) Trading Report - news.stocktradersdaily.com

Apr 01, 2025

Apr 01, 2025

Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 01, 2025

Mar 31, 2025

Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia

Mar 31, 2025

Mar 27, 2025

Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 27, 2025

Mar 27, 2025

Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada

Mar 27, 2025

Mar 21, 2025

Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Mar 21, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Mar 21, 2025

Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 18, 2025

Mar 15, 2025

Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 15, 2025

Mar 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025

Mar 13, 2025

Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq

Mar 13, 2025

Mar 13, 2025

Citigroup starts coverage of Kymera with $52 PT - TradingView

Mar 13, 2025

Mar 11, 2025

(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025

Mar 07, 2025

Why Kymera Therapeutics’ Stock is Making Waves - TipRanks

Mar 07, 2025

Mar 06, 2025

Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK

Mar 06, 2025

Mar 06, 2025

Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St

Mar 06, 2025

Mar 06, 2025

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance

Mar 06, 2025

Mar 06, 2025

What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025

A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily

Mar 05, 2025

Mar 05, 2025

New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 05, 2025

Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025

Mar 05, 2025

Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World

Mar 05, 2025

Mar 04, 2025

Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock - Investing.com

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics announces new performance-based stock plan - Investing.com India

Mar 03, 2025

Mar 03, 2025

Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks

Mar 03, 2025